The Journal of Headache and Pain

Groundbreaking work in migraine real-world evidence extends Verantos' lead in artificial intelligence for neurology

Retrieved on: 
Wednesday, July 19, 2023

PALO ALTO, Calif., July 19, 2023 /PRNewswire/ -- Verantos today announced two peer-reviewed publications on high-quality real-world data for migraine. The manuscripts describe the use of artificial intelligence (AI) on medical records to enable access to valuable clinical information such as headache severity, comorbid depression, associated symptoms, and a composite migraine impact score.

Key Points: 
  • The manuscripts describe the use of artificial intelligence (AI) on medical records to enable access to valuable clinical information such as headache severity, comorbid depression, associated symptoms, and a composite migraine impact score.
  • Using artificial intelligence to identify patients with migraine and associated symptoms and conditions within electronic health records " was published in BMC Medical Informatics and Decision Making.
  • This groundbreaking work builds on phenotyping to develop and validate a model of migraine outcomes that uses information typically available in routinely collected data.
  • Verantos' Migraine Pragmatic Registry applies the technology and methodology from these publications and is available today.

Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Friday, March 24, 2023

SEATTLE, March 24, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.

Key Points: 
  • ET
    SEATTLE, March 24, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.
  • New Trudhesa prescriptions increased by 24 percent from Q3 to Q4 2022 driven by an expanded, more efficient salesforce.
  • Reimbursement of all shipments is 60 percent for the fourth quarter 2022.
  • ET today to discuss the fourth quarter and full year 2022 financial results and provide a corporate and business update.